145 related articles for article (PubMed ID: 35166242)
21. Inhibition of tumor metastasis: functional immune modulation of the CUB domain containing protein 1.
Fukuchi K; Steiniger SC; Deryugina E; Liu Y; Lowery CA; Gloeckner C; Zhou B; Kaufmann GF; Quigley JP; Janda KD
Mol Pharm; 2010 Feb; 7(1):245-53. PubMed ID: 19916495
[TBL] [Abstract][Full Text] [Related]
22. CUB Domain-Containing Protein 1 (CDCP1) is a rational target for the development of imaging tracers and antibody-drug conjugates for cancer detection and therapy.
Khan T; Lyons NJ; Gough M; Kwah KKX; Cuda TJ; Snell CE; Tse BW; Sokolowski KA; Pearce LA; Adams TE; Rose SE; Puttick S; Pajic M; Adams MN; He Y; Hooper JD; Kryza T
Theranostics; 2022; 12(16):6915-6930. PubMed ID: 36276654
[No Abstract] [Full Text] [Related]
23. Regulation of inside-out β1-integrin activation by CDCP1.
Pollan SG; Huang F; Sperger JM; Lang JM; Morrissey C; Cress AE; Chu CY; Bhowmick NA; You S; Freeman MR; Spassov DS; Moasser MM; Carter WG; Satapathy SR; Shah K; Knudsen BS
Oncogene; 2018 May; 37(21):2817-2836. PubMed ID: 29511352
[TBL] [Abstract][Full Text] [Related]
24. CUB-domain containing protein 1 represses the epithelial phenotype of pancreatic cancer cells.
Miura S; Hamada S; Masamune A; Satoh K; Shimosegawa T
Exp Cell Res; 2014 Feb; 321(2):209-18. PubMed ID: 24384474
[TBL] [Abstract][Full Text] [Related]
25. Identification of CDCP1 as a hypoxia-inducible factor 2α (HIF-2α) target gene that is associated with survival in clear cell renal cell carcinoma patients.
Emerling BM; Benes CH; Poulogiannis G; Bell EL; Courtney K; Liu H; Choo-Wing R; Bellinger G; Tsukazawa KS; Brown V; Signoretti S; Soltoff SP; Cantley LC
Proc Natl Acad Sci U S A; 2013 Feb; 110(9):3483-8. PubMed ID: 23378636
[TBL] [Abstract][Full Text] [Related]
26. Elevated CDCP1 predicts poor patient outcome and mediates ovarian clear cell carcinoma by promoting tumor spheroid formation, cell migration and chemoresistance.
He Y; Wu AC; Harrington BS; Davies CM; Wallace SJ; Adams MN; Palmer JS; Roche DK; Hollier BG; Westbrook TF; Hamidi H; Konecny GE; Winterhoff B; Chetty NP; Crandon AJ; Oliveira NB; Shannon CM; Tinker AV; Gilks CB; Coward JI; Lumley JW; Perrin LC; Armes JE; Hooper JD
Oncogene; 2016 Jan; 35(4):468-78. PubMed ID: 25893298
[TBL] [Abstract][Full Text] [Related]
27. Dysregulated expression of cell surface glycoprotein CDCP1 in prostate cancer.
Yang L; Dutta SM; Troyer DA; Lin JB; Lance RA; Nyalwidhe JO; Drake RR; Semmes OJ
Oncotarget; 2015 Dec; 6(41):43743-58. PubMed ID: 26497208
[TBL] [Abstract][Full Text] [Related]
28. Proteolysis-induced N-terminal ectodomain shedding of the integral membrane glycoprotein CUB domain-containing protein 1 (CDCP1) is accompanied by tyrosine phosphorylation of its C-terminal domain and recruitment of Src and PKCdelta.
He Y; Wortmann A; Burke LJ; Reid JC; Adams MN; Abdul-Jabbar I; Quigley JP; Leduc R; Kirchhofer D; Hooper JD
J Biol Chem; 2010 Aug; 285(34):26162-73. PubMed ID: 20551327
[TBL] [Abstract][Full Text] [Related]
29. CDCP1 regulates the function of MT1-MMP and invadopodia-mediated invasion of cancer cells.
Miyazawa Y; Uekita T; Ito Y; Seiki M; Yamaguchi H; Sakai R
Mol Cancer Res; 2013 Jun; 11(6):628-37. PubMed ID: 23439492
[TBL] [Abstract][Full Text] [Related]
30. EGF inhibits constitutive internalization and palmitoylation-dependent degradation of membrane-spanning procancer CDCP1 promoting its availability on the cell surface.
Adams MN; Harrington BS; He Y; Davies CM; Wallace SJ; Chetty NP; Crandon AJ; Oliveira NB; Shannon CM; Coward JI; Lumley JW; Perrin LC; Armes JE; Hooper JD
Oncogene; 2015 Mar; 34(11):1375-83. PubMed ID: 24681947
[TBL] [Abstract][Full Text] [Related]
31. CUB-domain-containing protein 1 regulates peritoneal dissemination of gastric scirrhous carcinoma.
Uekita T; Tanaka M; Takigahira M; Miyazawa Y; Nakanishi Y; Kanai Y; Yanagihara K; Sakai R
Am J Pathol; 2008 Jun; 172(6):1729-39. PubMed ID: 18467693
[TBL] [Abstract][Full Text] [Related]
32. Effect of the tyrosine kinase inhibitor lapatinib on CUB-domain containing protein (CDCP1)-mediated breast cancer cell survival and migration.
Seidel J; Kunc K; Possinger K; Jehn C; Lüftner D
Biochem Biophys Res Commun; 2011 Oct; 414(1):226-32. PubMed ID: 21945930
[TBL] [Abstract][Full Text] [Related]
33. Structural requirements for cub domain containing protein 1 (CDCP1) and Src dependent cell transformation.
Kollmorgen G; Bossenmaier B; Niederfellner G; Häring HU; Lammers R
PLoS One; 2012; 7(12):e53050. PubMed ID: 23300860
[TBL] [Abstract][Full Text] [Related]
34. CUB domain-containing protein 1 and the epidermal growth factor receptor cooperate to induce cell detachment.
Law ME; Ferreira RB; Davis BJ; Higgins PJ; Kim JS; Castellano RK; Chen S; Luesch H; Law BK
Breast Cancer Res; 2016 Aug; 18(1):80. PubMed ID: 27495374
[TBL] [Abstract][Full Text] [Related]
35. The SRC-associated protein CUB Domain-Containing Protein-1 regulates adhesion and motility.
Benes CH; Poulogiannis G; Cantley LC; Soltoff SP
Oncogene; 2012 Feb; 31(5):653-63. PubMed ID: 21725358
[TBL] [Abstract][Full Text] [Related]
36. FBXL14 abolishes breast cancer progression by targeting CDCP1 for proteasomal degradation.
Cui YH; Kim H; Lee M; Yi JM; Kim RK; Uddin N; Yoo KC; Kang JH; Choi MY; Cha HJ; Kwon OS; Bae IH; Kim MJ; Kaushik N; Lee SJ
Oncogene; 2018 Oct; 37(43):5794-5809. PubMed ID: 29973690
[TBL] [Abstract][Full Text] [Related]
37. The CDCP1 Signaling Hub: A Target for Cancer Detection and Therapeutic Intervention.
Khan T; Kryza T; Lyons NJ; He Y; Hooper JD
Cancer Res; 2021 May; 81(9):2259-2269. PubMed ID: 33509939
[TBL] [Abstract][Full Text] [Related]
38. The tyrosine phosphatase SHP2 associates with CUB domain-containing protein-1 (CDCP1), regulating its expression at the cell surface in a phosphorylation-dependent manner.
Gandji LY; Proust R; Larue L; Gesbert F
PLoS One; 2015; 10(4):e0123472. PubMed ID: 25876044
[TBL] [Abstract][Full Text] [Related]
39. CDCP1: A promising diagnostic biomarker and therapeutic target for human cancer.
Qi X; Gao J; Li Z; Zhang G; Li J; Fu Y; Cai M; Wang H; Tong T
Life Sci; 2022 Jul; 301():120600. PubMed ID: 35504333
[TBL] [Abstract][Full Text] [Related]
40. KAI1 suppresses HIF-1α and VEGF expression by blocking CDCP1-enhanced Src activation in prostate cancer.
Park JJ; Jin YB; Lee YJ; Lee JS; Lee YS; Ko YG; Lee M
BMC Cancer; 2012 Mar; 12():81. PubMed ID: 22390300
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
